Japanese
version
issued
on |
No. |
Table of contents |
PDF |
| March 31, 2010 |
267 |
- Precautions on handling of lancing devices for capillary blood sampling
- Important Safety Information
(1)Bortezomib
(2)Methotrexate
- Revision of PRECAUTIONS (No. 214)
Warfarin Potassium (and 9 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [493 KB] |
| February 24, 2010 |
266 |
- Proper proceudures for soft contact lens care
- Important Safety Information
(1)Bicalutamide
(2)Fludarabine phosphate
- Revision of PRECAUTIONS (No. 213)
Amoxapine (and 11 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [607 KB] |
| January 27, 2010 |
265 |
- Handling of fire during Long-term Oxygen Therapy
- Important Safety Information
(1)Sorafenib tosilate
(2)Aripiprazole, spiperone, sulpiride, zotepine, nemonapride, pipamperone hydrochloride, pimozide, moperone hydrochloride
(3)Olanzapine, risperidone (oral dosage form), risperidone (injectable dosage form)
(4)Quetiapine fumarate
(5)Tandospirone citrate
- Revision of PRECAUTIONS (No. 212)
Acemetacin (and 14 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [491 KB] |
| December 25, 2009 |
264 |
- Safety measures for anaphylaxis and anaphylactoid symptoms associated with injectable antibiotics
- Important Safety Information
(1)Salazosulfapyridine
(2)Pethidine hydrochloride, pethidine hydrochloride / levallorphan tartrate
- Revision of PRECAUTIONS (No. 211)
Indometacin (oral dosage form) (and 7 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [601 KB] |
November 27, 2009 |
263 |
- Association between use of human insulin and insulin analogues and risk of cancer
- Important Safety Information
(1)Ivermectin
(2)Everolimus, gusperimus hydrochloride, cyclosporine (oral dosage form, injectable dosage form), tacrolimus hydrate (oral dosage form, injectable dosage form), basiliximab (genetical recombination), mycophenolate mofetil, muromonab-CD3
(3)Ciprofloxacin, ciprofloxacin hydrochloride
(4)Sunitinib malate
(5)Sorafenib tosilate
(6)Tegafur / gimeracil / oteracil potassium
(7)Bevacizumab (genetical recombination)
(8)Rosuvastatin calcium
- Revision of Precautions (No. 210)
(1)Pancuronium bromide, vecuronium bromide, rocuronium bromide (and 7 others)
(2)Blood circuits (and 3 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [616 KB] |
| October 28, 2009 |
262 |
- PMDA Medical Safety Information
- The Relief System for Sufferers from Adverse Drug Reactions and Disease Infected from Biological Products
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [488 KB] |
| September 29, 2009 |
261 |
- Drug-associated serious skin disorders
- SSRIs / SNRIs and harmful behavior to others
- Important Safety Information
(1)Varenicline tartrate
- Revision of PRECAUTIONS (No. 209)
Cibenzoline succinate (oral dosage form) (and 7 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Reports on adverse reactions associated with influenza vaccines in FY 2008
(Conclusion of the Vaccine Adverse Reaction Review Committee)
|
Full text [402 KB] |
| August 26, 2009 |
260 |
- Tricyclic and tetracyclic antidepressants, associated with aggression
- Important Safety Information
(1)Telmisartan
(2)Phenytoin, Phenytoin / Phenobarbital, Phenytoin / Phenobarbital / Caffeine and Sodium Benzoate, Phenytoin Sodium
- Revision of PRECAUTIONS (No. 208)
Lamotrigine (and 9 others)
- List of Products Subject to Early Post-marketing Phase Vigilance
|
Full text [330 KB] |
| July 30, 2009 |
259 |
- Important Safety Information
(1)Monobasic Sodium Phosphate Monohydrate and Anhydrous Dibasic Sodium Phosphate
- Revision of PRECAUTIONS (No. 207)
Blonanserin (and 4 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- About Oseltamivir Phosphate (Tamiflu)
<The brief summary of the review results of the investigation by the Subcommittee on Drug Safety (held on June 16, 2009)>
|
Full text [317 KB] |
| June 24, 2009 |
258 |
- Selective serotonin reuptake inhibitors (SSRIs) and aggression
- Important Safety Information
(1)Isoflurane
- Revision of PRECAUTIONS (No. 206)
Olmesartan medoxomil (and 3 others)
- List of products subject to Early Post-marketing Phase Vigilance
<Reference>
- Project for promoting safe use of drugs
- Manuals for Management of Individual Serious Adverse Drug Reactions
- Extension of cooperating hospitals in the project for "Japan Drug Information Institute in Pregnancy"
|
Full text [918 KB] |
| May 28, 2009 |
257 |
- Implementation of appropriate management / maintenance of automated external defibrillators (AEDs)
- Revision of PRECAUTIONS (No. 205)
Naproxen (and 7 others)
- List of products subject to Early Post-marketing Phase Vigilance
|
Full text [790 KB] |
